Yuri Peterson to Antineoplastic Agents
This is a "connection" page, showing publications Yuri Peterson has written about Antineoplastic Agents.
Connection Strength
0.660
-
A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem. 2006 May 05; 281(18):12445-50.
Score: 0.156
-
Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs. Molecules. 2022 Jun 08; 27(12).
Score: 0.120
-
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 08; 162(2):463-473.
Score: 0.105
-
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020 05 28; 63(10):5501-5525.
Score: 0.104
-
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem. 2018 03 22; 61(6):2589-2603.
Score: 0.090
-
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.
Score: 0.062
-
Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019 01 01; 79(1):231-241.
Score: 0.023